Core Laboratories (CLB) Non-Current Deffered Revenue (2022 - 2026)

Core Laboratories' Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at $29.9 million for Q2 2026.

• In Q2 2026, Non-Current Deffered Revenue rose 1.01% year-over-year to $29.9 million; the TTM figure through Jun 2026 stood at $29.9 million (up 1.01% YoY), while the FY2025 annual figure was $29.4 million, down 5.57% from the prior year.
• Non-Current Deffered Revenue for Q2 2026 stood at $29.9 million, up from $28.2 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $31.8 million in Q4 2022, with the low at $28.2 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $30.2 million (2024), against an average of $30.2 million.
• The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue rose 8.44% in 2024, then fell 5.57% in 2025.
• Core Laboratories' Non-Current Deffered Revenue stood at $31.8 million in 2022, then retreated by 3.99% to $30.5 million in 2023, then climbed by 1.87% to $31.1 million in 2024, then declined by 5.57% to $29.4 million in 2025, then rose by 1.9% to $29.9 million in 2026.
• Business Quant data shows CLB's Non-Current Deffered Revenue at $29.9 million in Q2 2026, $28.2 million in Q1 2026, and $29.4 million in Q4 2025.